 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
| How to use this System |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Chronic Myelogenous Leukemia (CML)
Chronic myelogenous leukemia (CML) is a cancer of the blood and bone marrow. All blood cells are made by stem cells in the bone marrow, which is the spongy tissue inside your bones. There are 3 types of blood cells: red cells, which carry oxygen to all the tissues in the body; white cells, which fight infection; and platelets, which allow the blood to clot to help stop bleeding when a blood vessel is damaged. In CML, the stem cells in the bone marrow make too many white blood cells, some of which never mature. These immature white blood cells collect in the bone marrow and blood. Eventually, the extra white blood cells crowd out the healthy red cells and platelets and interfere with the functioning of other organs. This causes the symptoms of CML.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Chronic Myelogenous Leukemia (CML) Study CAMN107AUS09
The purpose of this clinical trial is to determine if the study drug, nilotinib (Tasigna®), is safe and has beneficial effects in people who have chronic myelogenous leukemia (CML) in the chronic phase and a suboptimal molecular response to imatinib (Gleevec®). Nilotinib (Tasigna®), is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic-phase and accelerated-phase Philadelphia chromosome positive (Ph+) CML in adult patients who are resistant or intolerant to prior treatment including imatinib (Gleevec®).
Trial phase: Phase 2 Participation Duration: Participants will be taking the study drug daily for up to 5 years on this study. They will be required to return to the study doctor’s office at regular intervals so that their condition can be monitored and routine blood tests and safety evaluation can be carried out. Protocol Number: CAMN107AUS09 |
